Agencia Lei Va Hong
Concise Prescribing Info
Anaplastic lymphoma kinase (ALK) positive & metastatic non-small cell lung cancer (NSCLC).
Dosage/Direction for Use
PO 600 mg bd starting dose. 1st dose reduction: 450 mg bd; 2nd dose reduction: 300 mg bd.
Should be taken with food: Swallow whole, do not open or dissolve the contents of cap.
Special Precautions
Promptly investigate for interstitial lung disease (ILD)/pneumonitis in patient who presents w/ worsening of resp symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough & fever). Risk of symptomatic bradycardia. Monitor heart rate & BP regularly. Myalgia/musculoskeletal pain; creatine phosphokinase (CPK) elevations. Assess CPK levels every 2 wk for the 1st mth of treatment, & as clinically indicated. Renal impairment. Hepatotoxicity. Monitor liver function tests eg, ALT, AST, & total bilirubin every 2 wk during the 1st 3 mth of treatment, then once a mth thereafter & as clinically indicated. Female of reproductive potential must use effective contraception during treatment & for 1 wk after final dose. Males w/ female partners of reproductive potential must use effective contraception during treatment & for 3 mth following final dose. Pregnancy & lactation. Elderly ≥65 yr. Childn.
Adverse Reactions
Increased AST & ALT, increased alkaline phosphatase, increased creatine phosphokinase, hyperbilirubinemia, hyperglycemia, hypocalcemia, hypokalemia, increased creatinine, hypophosphatemia, hyponatremia; anemia, lymphopenia; fatigue, edema; constipation, nausea, diarrhea, vomiting; myalgia, back pain; rash; cough; headache; increased wt, vision disorder.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01ED03 - alectinib ; Belongs to the class of anaplastic lymphoma kinase (ALK) inhibitors. Used in the treatment of cancer.
ALECENSA cap 150 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in